- Credit Suisse says that Ventyx Biosciences Inc's VTYX topline Phase 1 MAD data for its allosteric TYK2 inhibitor, VTX958 establishes clear differentiation from other TYK2is and meaningfully de-risk the drug's profile.
- Credit Suisse raised the price target to $63 from $53 with an Outperform rating.
- VTYX plans on initiating Phase 2 Proof of Concept trials in psoriasis, psoriatic arthritis, and Crohn's disease (CD) in Q4.
- VTX958 achieved dose-dependent exposure/target coverage, with up to 24 hours of TYK2 IC50/IC90 coverage and class-leading coverage of its target cytokines, writes the analyst.
- Early data suggests VTX958 can achieve better exposure/TYK2 pathway suppression with a wider safety margin.
- According to Credit Suisse, VTX958 is particularly well positioned for success in CD, a ~$12 billion indication without any oral therapies that likely require greater TYK2 coverage than psoriasis for adequate disease management.
- VTYX trades at ~$700 million EV and funds into H1 2024.
- The analysts see the company offers a compelling investment opportunity with a highly favorable upside/downside.
- Price Action: VTYX shares are up 32.20% at $24.61 during the last check on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
